Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
COO 
The Cooper Companies, Inc. Common Stock (COO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/14/2025: COO (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 4.25% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 16.25B USD | Price to earnings Ratio 39.26 | 1Y Target Price 107.41 |
Price to earnings Ratio 39.26 | 1Y Target Price 107.41 | ||
Volume (30-day avg) 1993433 | Beta 1.02 | 52 Weeks Range 77.05 - 112.38 | Updated Date 04/1/2025 |
52 Weeks Range 77.05 - 112.38 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.57% | Operating Margin (TTM) 18.87% |
Management Effectiveness
Return on Assets (TTM) 3.8% | Return on Equity (TTM) 5.25% |
Valuation
Trailing PE 39.26 | Forward PE 20.96 | Enterprise Value 18693271552 | Price to Sales(TTM) 4.29 |
Enterprise Value 18693271552 | Price to Sales(TTM) 4.29 | ||
Enterprise Value to Revenue 4.88 | Enterprise Value to EBITDA 17.52 | Shares Outstanding 199956992 | Shares Floating 198619311 |
Shares Outstanding 199956992 | Shares Floating 198619311 | ||
Percent Insiders 0.61 | Percent Institutions 100.92 |
Analyst Ratings
Rating 4 | Target Price 112.01 | Buy 2 | Strong Buy 9 |
Buy 2 | Strong Buy 9 | ||
Hold 7 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
The Cooper Companies, Inc. Common Stock
Company Overview
History and Background
The Cooper Companies, Inc., founded in 1958, evolved from a manufacturer of sunglasses and contact lenses to a global medical device company focused on vision care and women's health. Significant milestones include acquisitions that expanded its product portfolio and market reach.
Core Business Areas
- CooperVision: CooperVision manufactures and sells a wide range of contact lenses, including spherical, toric, and multifocal lenses, as well as lens care products.
- CooperSurgical: CooperSurgical focuses on providing medical devices and solutions for women's health, including fertility, diagnostics, and surgical products.
Leadership and Structure
The company is led by a board of directors and a senior management team. Organizational structure is divided into business units based on its core business areas.
Top Products and Market Share
Key Offerings
- MyDay (CooperVision): MyDay is a family of silicone hydrogel daily disposable contact lenses. CooperVision holds a significant market share in the daily disposable contact lens market. Competitors include Alcon, Johnson & Johnson Vision, and Bausch + Lomb. The market size is billions in annual revenue.
- RI Witness (CooperSurgical): RI Witness is an innovative management system designed for fertility clinics. CooperSurgical has a leading position in the IVF market with the RI Witness system. Competitors include Vitrolife, and Planer PLC. The global market for IVF is in the billions.
Market Dynamics
Industry Overview
The medical device industry is characterized by technological innovation, regulatory scrutiny, and increasing demand due to an aging global population. Both vision care and women's health are experiencing growth.
Positioning
The Cooper Companies, Inc. Common Stock is a leading player in both the vision care and women's health markets. Competitive advantages include a diversified product portfolio and strong brand reputation.
Total Addressable Market (TAM)
The combined TAM for vision care and women's health exceeds $40 billion. The Cooper Companies, Inc. Common Stock holds a substantial share and is well-positioned for further growth.
Upturn SWOT Analysis
Strengths
- Diversified Product Portfolio
- Strong Brand Reputation
- Global Presence
- Innovation in Contact Lens Technology
- Leading Position in Women's Health
Weaknesses
- Exposure to Currency Fluctuations
- Dependence on Acquisitions for Growth
- Competition from Larger Players
- Product Liability Risks
Opportunities
- Expanding into Emerging Markets
- Developing New Contact Lens Technologies
- Acquiring Complementary Businesses
- Increasing Demand for Women's Health Products
Threats
- Intense Competition
- Regulatory Changes
- Economic Downturns
- Technological Disruption
Competitors and Market Share
Key Competitors
- Alcon (ALC)
- Johnson & Johnson (JNJ)
- Bausch & Lomb (BLCO)
- Vitrolife (VITO.ST)
Competitive Landscape
Evaluate The Cooper Companies, Inc. Common Stocku2019s advantages and disadvantages compared to its competitors.
Major Acquisitions
Paragard IUD
- Year: 2017
- Acquisition Price (USD millions): 1100
- Strategic Rationale: Expanded CooperSurgical's women's health product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Discuss The Cooper Companies, Inc. Common Stock's growth trends over the past years.
Future Projections: Provide projections for The Cooper Companies, Inc. Common Stock's future growth based on analyst estimates.
Recent Initiatives: Highlight recent strategic initiatives undertaken by The Cooper Companies, Inc. Common Stock.
Summary
The Cooper Companies is a stable and diversified medical device company with solid positions in both vision care and women's health. Its acquisitions have fueled growth, but dependence on them is a risk. Competition is high in both sectors, but The Cooper Companies' innovative products and strong brands offer a competitive edge. Maintaining a strong balance sheet and navigating regulatory challenges will be critical for future success.
Similar Companies
ALC
Alcon AG
ALC
Alcon AG
BLCO
Bausch + Lomb Corp
BLCO
Bausch + Lomb Corp
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market conditions are subject to change, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About The Cooper Companies, Inc. Common Stock
Exchange NASDAQ | Headquaters San Ramon, CA, United States | ||
IPO Launch date 1983-12-30 | President, CEO & Non-Independent Director Mr. Albert G. White III | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 16000 | Website https://www.coopercos.com |
Full time employees 16000 | Website https://www.coopercos.com | ||
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia; and spherical lense, including lenses that correct near and farsightedness in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including paragard contraceptive intrauterine devices; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.